SHSE:688513's Quick Ratio is ranked worse than 51.95% of 1409
companies
in the Biotechnology industry
Industry Median: 3.6
vs SHSE:688513: 3.38
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Chengdu Easton Biopharmaceuticals Co Quick Ratio Related Terms
Chengdu Easton Biopharmaceuticals Co Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co Quick Ratio Chart
SHSE:688513 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chengdu Easton Biopharmaceuticals Co Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's Quick Ratio falls into.
Chengdu Easton Biopharmaceuticals Co Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a Quick Ratio of 3.38 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. This is 16% above median its historical median of 2.91. Over the past decade, Chengdu Easton Biopharmaceuticals Co's Quick Ratio has ranged from 1.92 to 5.12. According to the industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #732 out of 1409 companies in the Biotechnology industry, placing it in the top 52%.
Is Chengdu Easton Biopharmaceuticals Co's Quick Ratio too high?
Chengdu Easton Biopharmaceuticals Co's current Quick Ratio of 3.38 is 16% above median its 10-year median of 2.91. Over the past 10 years, this metric has ranged from a low of 1.92 to a high of 5.12. The Biotechnology industry median Quick Ratio is 3.60. Chengdu Easton Biopharmaceuticals Co's value of 3.38 is 6.1% below this industry median. Based on the distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #732 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chengdu Easton Biopharmaceuticals Co ranks #732 out of 1409 companies for Quick Ratio. This places Chengdu Easton Biopharmaceuticals Co in the lower half of its industry. The industry median Quick Ratio is 3.60. Chengdu Easton Biopharmaceuticals Co's value of 3.38 is 6.1% below this benchmark. Historically, Chengdu Easton Biopharmaceuticals Co's own Quick Ratio has ranged from 1.92 to 5.12 over the past decade. While the company's 10-year median is 2.91 vs. the industry median of 3.60, Chengdu Easton Biopharmaceuticals Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chengdu Easton Biopharmaceuticals Co's current Quick Ratio of 3.38 is 6.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Chengdu Easton Biopharmaceuticals Co and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chengdu Easton Biopharmaceuticals Co's current Quick Ratio is 3.38, which is 16% above median its own 10-year median of 2.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥47.90, compared to a current price of ¥55.10 — trading 15% above its estimated fair value. The current Quick Ratio is 3.38, which is 16% above median its 10-year median of 2.91 and 6.1% below the Biotechnology industry median of 3.60. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current Quick Ratio is 3.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued.
The current stock price of ¥55.10 is trading 15% above its estimated GF Value™ of ¥47.90.
GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Modestly Overvalued.
Key valuation signals for SHSE:688513:
Quick Ratio: 3.38 (16% above median its 10-year median of 2.91)
GF Value™: ¥47.90 vs. price of ¥55.10 (15% above fair value)
Industry Position: 6.1% below the Biotechnology median (#732 of 1409)
No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chengdu Easton Biopharmaceuticals Co Business Description
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
95GF Score
Get the complete analysis for SHSE:688513
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688513 has been successfully added to your 
